● Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Condition: Type 2 Diabetes Mellitus · Type 2 Diabetes With Chronic Kidney Disease · Sponsor: AstraZeneca

PhasePhase 3

Planned participants900

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (169)

Research Site	Peoria, Arizona, United States	Not Yet Recruiting
Research Site	Surprise, Arizona, United States	Not Yet Recruiting
Research Site	Concord, California, United States	Not Yet Recruiting
Research Site	Sacramento, California, United States	Not Yet Recruiting
Research Site	Victorville, California, United States	Not Yet Recruiting
Research Site	Fleming Island, Florida, United States	Not Yet Recruiting
Research Site	Lauderdale Lakes, Florida, United States	Not Yet Recruiting
Research Site	Leesburg, Florida, United States	Not Yet Recruiting
Research Site	Miami Lakes, Florida, United States	Not Yet Recruiting
Research Site	Ocoee, Florida, United States	Not Yet Recruiting
Research Site	Orlando, Florida, United States	Not Yet Recruiting
Research Site	Braintree, Massachusetts, United States	Not Yet Recruiting

+ 157 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07662135